A Clinical Study of B007 in the Treatment of Pemphigus.
ConditionPemphigus
Trial statusRecruiting
Trial phasePhase 2, Phase 3
Trial typeInterventional
Biological sexAll
Age18-75
SponsorShanghai Jiaolian Drug Research and Development Co., Ltd
About this trial
The purpose of this study is to evaluate the efficacy and safety of B007 in subjects with pemphigus.
Eligibility criteria
Qualifiers
Subjects who voluntarily participate in this study and sign informed consent form;
Subjects who meet the clinical manifestations of pemphigus and are clinically diagnosed as prescribed diseases;
Subjects with first diagnosis or relapse;
Subjects who have the ability to follow the study protocol as determined by the investigator.
Disqualifiers
Subjects diagnosed with prescribed diseases;
Since the diagnosis of pemphigus, Disease duration>4 years;
Subjects using prescribed drugs;
Presence of a specified disease or history of disease;
Trial design
Treatments tested in this trial
- B007
Treatment groups
132 Participants
are divided into 1 treatment groupSponsors and collaborators
Shanghai Jiaolian Drug Research and Development Co., Ltd
Lead sponsor
Shanghai Pharmaceuticals Holding Co., Ltd
Collaborator
Source ClinicalTrials.gov